Lexicon Pharmaceuticals | LXRX - Vertriebs- Und Verwaltungskosten





Vertriebs- Und Verwaltungskosten Veränderung Datum
Abbott USD 4.27B 669M 2026-09
Acadia Pharmaceuticals USD 146.88M 1.69M 2026-09
Agios Pharmaceuticals USD 51.55M 13.09M 2026-06
Akebia Therapeutics USD 23.53M 3.19M 2025-12
Alnylam Pharmaceuticals USD 342M 5.92M 2026-09
AstraZeneca USD 4.07B 1.73B 2026-09
BioMarin Pharmaceutical USD 333.64M 61.91M 2026-09
Coherus Biosciences USD 15M 6.26M 2025-12
Eli Lilly USD 3.12B 305M 2026-09
Halozyme Therapeutics USD 58.24M 1.24M 2026-09
Illumina USD 281M 8M 2026-09
Insmed USD 253.03M 5.56M 2026-09
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
J&J USD 6.25B 168M 2026-09
Lexicon Pharmaceuticals USD 3.98M 195K 2025-12
MacroGenics USD 7.9M 1.81M 2026-06
MannKind USD 61.41M 3.11M 2026-09
Merck USD 2.86B 25M 2026-09
Moderna USD 282M 66M 2026-09
Novartis USD 3.08B 163M 2026-09
PTC Therapeutics USD 80.63M 6.74M 2026-06
Puma Biotechnology USD 16.82M 8.15M 2024-09
Sarepta Therapeutics USD 118.61M 11.01M 2026-09
Thermo Fisher Scientific USD 1.86B 46M 2026-09
Ultragenyx Pharmaceutical USD 97M 9M 2026-09
United Therapeutics USD 184.1M 22.6M 2026-09
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12